cardiovascular benefits of glp-1 agonists Frontiers Glucagon-like peptide 1 receptor agonists:

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

Incretin mimetics considerably expanded their proven benefits beyond obesity in 2024

Arizona OPEN ACCESS PUBLISHED:30 October 2024 CITATION:Chakkera, S

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence